Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

ClinicalTrials.gov ID: NCT02792218

Public ClinicalTrials.gov record NCT02792218. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

Study identification

NCT ID
NCT02792218
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
930 participants

Conditions and interventions

Interventions

  • Matching placebo of ofatumumab subcutaneous injections Drug
  • Ofatumumab subcutaneous injection Drug
  • Teriflunomide capsule Drug
  • Teriflunomide-matching placebo capsules Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 19, 2016
Primary completion
Jul 4, 2019
Completion
Jul 19, 2020
Last update posted
Sep 30, 2021

2016 – 2020

United States locations

U.S. sites
56
U.S. states
24
U.S. cities
53
Facility City State ZIP Site status
Novartis Investigative Site Phoenix Arizona 85013
Novartis Investigative Site Berkeley California 94705
Novartis Investigative Site Fullerton California 92835
Novartis Investigative Site Sacramento California 95817
Novartis Investigative Site Washington D.C. District of Columbia 20007
Novartis Investigative Site Atlantis Florida 33462-6608
Novartis Investigative Site Delray Beach Florida 33445
Novartis Investigative Site Hollywood Florida 33021
Novartis Investigative Site Loxahatchee Groves Florida 33470
Novartis Investigative Site Miami Florida 33032
Novartis Investigative Site Miami Florida 33136
Novartis Investigative Site Naples Florida 34102
Novartis Investigative Site North Palm Beach Florida 33408
Novartis Investigative Site Pensacola Florida 32514
Novartis Investigative Site Port Charlotte Florida 33952
Novartis Investigative Site Sunrise Florida 33351
Novartis Investigative Site Vero Beach Florida 32960
Novartis Investigative Site West Palm Beach Florida 33407
Novartis Investigative Site Savannah Georgia 31406
Novartis Investigative Site Honolulu Hawaii 96817
Novartis Investigative Site Chicago Illinois 60612
Novartis Investigative Site Northbrook Illinois 60062
Novartis Investigative Site Indianapolis Indiana 46202
Novartis Investigative Site Des Moines Iowa 50314-2611
Novartis Investigative Site Kansas City Kansas 66160
Novartis Investigative Site Overland Park Kansas 66210
Novartis Investigative Site Alexandria Louisiana 71301
Novartis Investigative Site Baton Rouge Louisiana 70810
Novartis Investigative Site Clinton Township Michigan 48035
Novartis Investigative Site Detroit Michigan 48201
Novartis Investigative Site Golden Valley Minnesota 55422
Novartis Investigative Site Chesterfield Missouri 63017
Novartis Investigative Site Ozark Missouri 65721
Novartis Investigative Site St Louis Missouri 63110
Novartis Investigative Site Las Vegas Nevada 89106
Novartis Investigative Site Latham New York 12110
Novartis Investigative Site Charlotte North Carolina 28204
Novartis Investigative Site Raleigh North Carolina 27607
Novartis Investigative Site Winston-Salem North Carolina 27103
Novartis Investigative Site Winston-Salem North Carolina 27157
Novartis Investigative Site Cleveland Ohio 44195
Novartis Investigative Site Oklahoma City Oklahoma 73104
Novartis Investigative Site Spartanburg South Carolina 29303
Novartis Investigative Site Johnson City Tennessee 37604
Novartis Investigative Site Knoxville Tennessee 37920
Novartis Investigative Site Dallas Texas 75246
Novartis Investigative Site El Paso Texas 79935
Novartis Investigative Site Houston Texas 77074
Novartis Investigative Site Round Rock Texas 78681
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site San Antonio Texas 78258
Novartis Investigative Site Virginia Beach Virginia 23456
Novartis Investigative Site Green Bay Wisconsin 54311
Novartis Investigative Site Madison Wisconsin 53792
Novartis Investigative Site Milwaukee Wisconsin 53215
Novartis Investigative Site Neenah Wisconsin 54956

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02792218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 30, 2021 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02792218 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →